Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Second Attempt
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With the positive results of the ADVANCE II study of Bristol-Myers Squibb/Pfizer's apixaban now offsetting the failed non-inferiority of the earlier ADVANCE I study, the ADVANCE III study is shaping up to be the tie-breaker for how the investigational anticoagulant stacks up against Sanofi-Aventis' low molecular weight heparin Lovenox (enoxaparin) in patients undergoing orthopedic surgery
You may also be interested in...
Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
The experimental anticoagulant's win over aspirin in patients intolerant to or unsuitable for warfarin therapy may allow a narrower indication.
Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
Bristol-Myers Squibb/Pfizer got incremental good news and a nice addition to the safety database for their experimental anticoagulant apixaban when a Phase III study was ended early for efficacy at preventing stroke compared to aspirin. The next big read-out for the oral Factor Xa inhibitor, though, will be in the first half of 2011, when results of a major head-to-head contest against warfarin in that setting are due
Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
Bristol-Myers Squibb/Pfizer got incremental good news and a nice addition to the safety database for their experimental anticoagulant apixaban when a Phase III study was ended early for efficacy at preventing stroke compared to aspirin. The next big read-out for the oral Factor Xa inhibitor, though, will be in the first half of 2011, when results of a major head-to-head contest against warfarin in that setting are due